Matt leads the development of a new technology platform applying our proptechnology to design new adenovirus-based vectors to target cancer and infectious diseases.
He joined SpyBiotech in 2017 from King’s College, London where he spent several years researching the virology of HIV. He is a specialist in the development of novel adenovirus-based vaccine vectors - common viruses engineered so that they are non-infectious but can generate a protective immune response.
After taking an undergraduate degree in Biochemistry from Oxford University, Matt moved to the renowned Jenner Institute to complete his doctorate. ChAdOX1, the novel chimpanzee adenovirus vector he created there, has been employed successfully in multiple clinical vaccine trials and is patent-protected in both the EU and US.